Executive Summary
Geneoscopy challenges Exact Sciences' '781 patent on grounds of obviousness (103) related to colorectal cancer diagnostics. The petitioner argues that combining known methods for fecal sample processing, such as DNA methylation and blood protein testing, renders the claims unpatentable over prior art references. This challenge targets multiple diagnostic claim sets across the patent.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Geneoscopy, Inc. vs Exact Sciences Corporation is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
CommScope Technologies LLC et al.vsBelden Canada ULC et al.
CommScope Technologies LLC filed an IPR petition challenging 49 claims related to modular cassette systems used in fiber optics. The petitioner argues that the challenged claims are anticipated or rendered obvious by prior art combinations involving Fukui, Sedor, and Sauter.
Luxottica of America Inc., et al.vsE-Vision Optics, LLC
The PTAB found all 26 challenged claims unpatentable based on obviousness (35 U.S.C. § 103). The Petitioner successfully demonstrated that the claimed features of smart eyewear were taught by combinations of prior art references, including Jannard, Rosenblatt, Chen, and Nielsen. This final decision significantly weakens the patent's validity in the wearable technology space.
NULIDS, LLCvsBlephEx, LLC
NULIDS challenges BlephEx's patent (11083621) in an IPR petition, arguing that the device for ocular disorder treatment is obvious. The petitioner relies on combinations of prior art references including Grenon I, Grenon II, Nichamin, Colin, and Shabo to invalidate claims 1-6, 9-18.
Askeladden L.L.C.vsIntercurrency Software LLC
Askeladden L.L.C. filed a petition challenging the validity of Intercurrency Software LLC's patent (US 10062107) before the PTAB. The petitioner asserts that the claims are unpatentable over prior art based on multiple grounds of obviousness under 35 U.S.C. § 103 and novelty under 35 U.S.C. § 102.
Honeywell International Inc.vsDSM IP Assets, B.V. et al.
Honeywell International Inc.'s IPR challenge against DSM IP Assets, B.V. et al. was denied by the PTAB. The Board found that the Petitioner failed to meet the reasonable likelihood standard for obviousness over various prior art combinations in the field of biomedical devices and polymer fibers.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.